Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C33H50N4O6S.CH4O3S |
Molecular Weight | 726.944 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC(C)(C)S(=O)(=O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC3CCCCC3)[C@@H](O)[C@@H](O)C4CC4
InChI
InChIKey=LYIKIXHUJZIDKE-KTASVBIRSA-N
InChI=1S/C33H50N4O6S.CH4O3S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24;1-5(2,3)4/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40);1H3,(H,2,3,4)/t25-,27+,28+,29+,30-;/m1./s1
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C33H50N4O6S |
Molecular Weight | 630.838 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P00797 Gene ID: 5972.0 Gene Symbol: REN Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8498974 |
0.7 nM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of remikiren as the first orally active renin inhibitor. | 1993 Feb |
|
Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals. | 1996 Mar |
|
Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. | 2005 Feb |
|
Purification and characterization of recombinant human renin for X-ray crystallization studies. | 2008 Jun 26 |
|
Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. | 2008 May |
|
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. | 2009 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8783774
Patients with essential hypertension: 600 mg orally for 8 days
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:31:12 GMT 2023
by
admin
on
Fri Dec 15 15:31:12 GMT 2023
|
Record UNII |
1Y25T426Y9
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1Y25T426Y9
Created by
admin on Fri Dec 15 15:31:12 GMT 2023 , Edited by admin on Fri Dec 15 15:31:12 GMT 2023
|
PRIMARY | |||
|
141078-87-7
Created by
admin on Fri Dec 15 15:31:12 GMT 2023 , Edited by admin on Fri Dec 15 15:31:12 GMT 2023
|
PRIMARY | |||
|
131634716
Created by
admin on Fri Dec 15 15:31:12 GMT 2023 , Edited by admin on Fri Dec 15 15:31:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |